Bioverativ Hits The Street Ready To Expand In Blood Disorders

Bioverativ will spin out from Biogen Feb. 1 as a biotech focused on rare blood disorders, particularly hemophilia. With two marketed drugs, a lifecycle management strategy and leverage to bring in new assets, CEO John Cox says the company is ready to go it alone.